Shuttle Pharmaceuticals Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) on August 21, 2024. The filing addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance and reporting delays rather than financial performance data.
Material Changes and Events
- Nasdaq Non-Compliance: The company received a notice of non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024.
- Cause of Delay: The delay stems from a re-audit of financial statements for the year ended December 31, 2022. This re-audit was necessitated by SEC sanctions against the company's former auditor, B.F. Borgers CPA, PC.
- Current Status: The current auditor, Forvis Mazars, LLP, is re-auditing the 2022 statements. The company is preparing an amended Form 10-K/A for 2023 and an amended Form 10-Q for the quarter ended March 31, 2024, to include restated information.
Outlook, Risks, and Management Commentary
- Compliance Plan: Management anticipates filing the amended reports within the next several days, followed by the Q2 2024 Quarterly Report, which should result in automatic reinstatement of compliance.
- Contingency: If additional time is required, Nasdaq rules allow the company to submit a compliance plan within 60 days, potentially granting up to 180 days to regain compliance.
- Listing Status: The Nasdaq Notice has no immediate effect on the listing of the company's common stock on the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the filing dates of the amended Form 10-K/A (2023) and Form 10-Q (Q1 2024) to confirm the timeline for resolving the delisting risk.
- Review the upcoming Q2 2024 Form 10-Q once filed to assess the impact of the restatements on current financial health.
- Monitor for any further communications from Nasdaq regarding the company's compliance status if the anticipated filing timeline is missed.
- Confirm the extent of the restatements in the 2022 financials to understand the magnitude of the accounting adjustments.